Charles River Laboratories International (CRL) Depreciation & Amortization (CF) (2016 - 2025)
Charles River Laboratories International has reported Depreciation & Amortization (CF) over the past 17 years, most recently at $78.3 million for Q4 2025.
- Quarterly results put Depreciation & Amortization (CF) at $78.3 million for Q4 2025, down 23.34% from a year ago — trailing twelve months through Dec 2025 was $403.3 million (up 11.49% YoY), and the annual figure for FY2025 was $403.3 million, up 11.49%.
- Depreciation & Amortization (CF) for Q4 2025 was $78.3 million at Charles River Laboratories International, down from $85.2 million in the prior quarter.
- Over the last five years, Depreciation & Amortization (CF) for CRL hit a ceiling of $120.4 million in Q1 2025 and a floor of $61.5 million in Q1 2021.
- Median Depreciation & Amortization (CF) over the past 5 years was $78.0 million (2023), compared with a mean of $82.4 million.
- Peak annual rise in Depreciation & Amortization (CF) hit 41.01% in 2025, while the deepest fall reached 23.34% in 2025.
- Charles River Laboratories International's Depreciation & Amortization (CF) stood at $67.2 million in 2021, then increased by 15.32% to $77.5 million in 2022, then increased by 3.83% to $80.5 million in 2023, then increased by 26.82% to $102.1 million in 2024, then dropped by 23.34% to $78.3 million in 2025.
- The last three reported values for Depreciation & Amortization (CF) were $78.3 million (Q4 2025), $85.2 million (Q3 2025), and $119.5 million (Q2 2025) per Business Quant data.